Association between molecular subtype membership or hypoxia-associated gene expression signatures and clinical outcomes in the CALGB 90601 (Alliance) phase 3 clinical trial of gemcitabine and cisplatin (GC) plus bevacizumab (B) or placebo (P).
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Johns Hopkins University, Johns Hopkins Hospital, Johns Hopkins Medicine, Duke Medical Center, Duke University, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, University of Chicago, The Ohio State University Wexner Medical Center, NewYork–Presbyterian Hospital, Weill Cornell Medicine
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: closed
Funder: National Institutes of Health
OpenAlex ID: W4286295660